Efficacy and Safety of Biosimilar SAR342434 Insulin Lispro in Adults with Type 2 Diabetes, Also Using Insulin Glargine: SORELLA 2 Study

Схожие документы

• Anti-Insulin Antibodies and Adverse Events with Biosimilar Insulin Lispro Compared with Humalog Insulin Lispro in People with Diabetes
  по: Home, Philip, et al.
  Опубликовано: (2018)
• Safety of Insulin Lispro and a Biosimilar Insulin Lispro When Administered Through an Insulin Pump
  по: Thrasher, James, et al.
  Опубликовано: (2018)
• Safety, Immunogenicity, and Glycemic Control of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Also Using Insulin Glargine: 12-Month Results from the GEMELLI 1 Trial
  по: Garg, Satish K., et al.
  Опубликовано: (2020)
• Efficacy, Safety, and Immunogenicity of Insulin Aspart Biosimilar SAR341402 Compared with Originator Insulin Aspart in Adults with Diabetes (GEMELLI 1): A Subgroup Analysis by Prior Type of Mealtime Insulin
  по: Shah, Viral N., et al.
  Опубликовано: (2021)
• Efficacy and Safety of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Treated for 26 Weeks with Multiple Daily Injections in Combination with Insulin Glargine: A Randomized Open-Label Trial (GEMELLI 1)
  по: Garg, Satish K., et al.
  Опубликовано: (2020)